期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病细胞表面分子抗原的靶向治疗 被引量：2

Monoclonal antibody therapy targeting surface antigens of leukemic cells
原文传递
导出
作者 孟凡义 扶云碧
机构地区 南方医科大学附属南方医院血液科
出处 《中华医学杂志》 CAS CSCD 北大核心 2005年第7期441-443,共3页 National Medical Journal of China
基金 广东省社会发展攻关课题基金资助项目(B30202)
关键词 抗原 单抗 白血病细胞 靶向治疗 CD20 表面分子 非霍杰金淋巴瘤 “生物导弹” 杀灭 应用
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc),2003,39 Suppl C:1-16.
  • 2Feldman E, Kalaycio M,Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia,2003, 17:314-318.
  • 3Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol,2001,19:3244-3254.
  • 4Bross PF,Beitz J,Chen G,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res, 2001,7:1490-1496.
  • 5Jurcic JG, Larson SM, Sgouros G. Targeted alpha particle immunotherapy for myeloid leukemia. Blood,2002, 100:1233-1239.
  • 6Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant,2003, 32:549-556.
  • 7Faderl S, Thomas DA, O′Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood,2003,101:3413-3415.
  • 8Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study. Blood, 2002, 99: 3554-3561.
  • 9Lundin J, Kimby E, Bjrkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood,2002,100:768-773.
  • 10Uppenkamp M, Engert A, Diehl V,et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol,2002, 81:26-32.

同被引文献21

  • 1孟凡义,徐兵,杜欣,汪明春,朱康儿.氟达拉滨联合不同剂量阿糖胞苷治疗复发、难治性急性白血病86例分析[J].中华血液学杂志,2006,27(6):419-420. 被引量：14
  • 2Hughes TP,Kaeda J,Brandford S,et al.Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chroninc myeloid leukemia.N Engl J Med,2003,349(15):1421
  • 3Sawyers CL.Chronic myeloid leukemia.N Engl J Med,1999,340(17):1330
  • 4Thijsen S,Schuurhuis G,van Oostveen J,et al.Chronic myeloid leukemia from basics to bedside.Leukemia,1999,13(11):1646
  • 5Kantarjian HM,Cortes JE,O'Brien S,et al.Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadephia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.Blood,2004,104 (7):1979
  • 6Gabert J,Beillard E,van der Velden VH,et al.Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program.Leukemia,2003,17(12):2318
  • 7Beillard E,Pallisgaard N,van der Velden VH,et al.Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a europe against cancer program.Leukemia,2003,17(12):2474
  • 8von Stackelberg A,Hartmann R, Buhrer C,et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia [ J ], Blood, 2008,111 (5) : 2573-2580.
  • 9Kern W, Aul C, Masehmeyer G, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia:results of a ageajusted prospective randomized comparison [J]. Leukemia, 1998,12 (7) : 1049.
  • 10Giles F J, Cortes J E, Kantarjian H M, et al. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia [J]. Leuk Res, 2004,28 (4) : 353-357.

引证文献2

二级引证文献5

中华医学杂志
2005年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部